文献速递病毒性肝炎细菌感染、耐药与抗菌药物

类风湿关节炎患者接受生物制剂治疗中的乙型肝炎病毒再激活

Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Biologics Treatment.
PubMed 文献 · J Infect Dis · 2017-01-01

该研究纳入123例HBsAg阳性且未接受抗HBV预防治疗的类风湿关节炎患者,随访3459人月,30例(24.4%)发生HBV再激活。糖皮质激素显著增加再激活风险,糖皮质激素联合bDMARDs和sDMARDs风险最高(aHR=5.14),bDMARDs中利妥昔单抗风险最大(aHR=16.51)。

要点

  • 糖皮质激素显著增加RA患者HBV再激活风险。
  • 糖皮质激素联合bDMARDs和sDMARDs的再激活风险最高(aHR=5.14)。
  • 接受bDMARDs者中利妥昔单抗再激活风险最大(aHR=16.51)。

核心结论

  • 糖皮质激素对RA患者HBV再激活有不利影响。
  • 应根据不同免疫抑制方案组合的HBV再激活风险来论证抗病毒预防策略。

研究设计与样本

  • 研究纳入2334例有HBsAg数据的RA患者,其中123例HBsAg阳性且未接受抗HBV预防治疗者入组。
  • 入组患者接受不同单药或联合免疫抑制治疗,其中36例接受bDMARDs。

主要发现

  • 随访3459人月期间,30例(24.4%)发生HBV再激活。
  • 多因素Cox模型显示糖皮质激素显著增加HBV再激活风险。
  • 糖皮质激素联合bDMARDs和sDMARDs的再激活风险最高(aHR=5.14;95%CI=1.77-14.92;P=.003)。
  • 接受bDMARDs者中利妥昔单抗再激活风险最大(aHR=16.51;95%CI=1.82-149.67;P=.01)。

临床怎么用

  • 对HBsAg阳性RA患者启动免疫抑制治疗前应评估HBV再激活风险。
  • 尤其使用糖皮质激素联合bDMARDs和sDMARDs或利妥昔单抗时,应考虑抗病毒预防策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immunosuppressants can induce hepatitis B virus (HBV) reactivation; however, informative data about the risk of different immunosuppressive regimens, including biologics, on HBV reactivation (HBVr) among patients with rheumatoid arthritis (RA) are incomplete. METHODS: Among 2334 RA patients who had available hepatitis B surface antigen (HBsAg) data, 123 patients positive for HBsAg who were not receiving anti-HBV prophylaxis were enrolled. These patients were undergoing varied mono or combination immunosuppressive therapy, including 36 who were receiving biological disease-modifying antirheumatic drugs (bDMARDs). RESULTS: During 3459 person-months of follow-up, 30 (24.4%) patients developed HBVr. The multivariate Cox proportional hazard models showed that glucocorticoid significantly increased the risk of HBVr. Among all kinds of immunosuppressive treatments, glucocorticoid in combination with bDMARDs and synthetic disease-modifying antirheumatic drugs (sDMARDs) had the highest risk of HBVr (adjusted hazard ratio [HR] = 5.14; 95% confidence interval [CI] = 1.77-14.92; P = .003). Rituximab had the greatest risk for HBVr (adjusted HR = 16.51; 95% CI = 1.82-149.67; P = .01) among the patients who received bDMARDs. CONCLUSIONS: Glucocorticoid has a detrimental effect on HBVr in RA patients. Antiviral prophylactic strategies should be justified according to the risk of HBVr under different combinations of immunosuppressive therapy in rheumatic patients.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Chen MH, Chen MH, Liu CY, et al. Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Biologics Treatment. J Infect Dis. 2017. PMID: 28011918. doi:10.1093/infdis/jiw606

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。